CD138
Jump to navigation
Jump to search
CD138, also known as Syndecan-1, is an immunostain that marks plasma cells.
Positive
- Plasma cells.[1]
- Plasma cell neoplasm.
- Triple negative breast cancer.[2]
- Plasmacytoid urothelial carcinoma.[3]
See also
References
- ↑ Humphrey, Peter A; Dehner, Louis P; Pfeifer, John D (2008). The Washington Manual of Surgical Pathology (1st ed.). Lippincott Williams & Wilkins. pp. 554. ISBN 978-0781765275.
- ↑ Lim, GH.; Tan, PH.; Jara-Lazaro, AR.; Thike, AA.; Sim, WC.; Yap, VB.; Yip, GW. (Sep 2014). "Syndecan-1 is a potential biomarker for triple-positive breast carcinomas in Asian women with correlation to survival.". Singapore Med J 55 (9): 468-72. PMID 25273930.
- ↑ Zhang, W.; Jiang, YX.; Liu, Y.; Yu, WJ.; Zhao, H.; Li, YJ. (Jul 2013). "[Plasmacytoid urothelial carcinoma of the urinary bladder: a clinicopathologic study of 16 cases].". Zhonghua Bing Li Xue Za Zhi 42 (7): 433-7. PMID 24246859.
.